Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 462.77M P/E - EPS this Y 10.10% Ern Qtrly Grth -
Income -177.12M Forward P/E -3.15 EPS next Y 7.00% 50D Avg Chg -22.00%
Sales 1.2M PEG -0.05 EPS past 5Y - 200D Avg Chg -19.00%
Dividend N/A Price/Book 4.07 EPS next 5Y 54.70% 52W High Chg -50.00%
Recommedations 2.20 Quick Ratio 5.42 Shares Outstanding 246.24M 52W Low Chg 11.00%
Insider Own 1.67% ROA -50.67% Shares Float 100.03M Beta 1.28
Inst Own 82.16% ROE -168.50% Shares Shorted/Prior 21.91M/21.07M Price 1.89
Gross Margin - Profit Margin - Avg. Volume 2,655,380 Target Price 5.50
Oper. Margin -6,657.69% Earnings Date Apr 30 Volume 1,578,230 Change -2.58%
About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals, Inc. News
04/18/24 Lexicon Pharmaceuticals to Host 2024 Investor Day
04/16/24 All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
04/03/24 Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03/25/24 Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
03/13/24 Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
03/12/24 New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
03/11/24 Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
03/11/24 Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
03/11/24 Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
03/11/24 Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
02/29/24 Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for
02/22/24 15 Hot Penny Stocks On the Move
01/31/24 3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts
01/23/24 3 of the Fastest-Growing Stocks on the Planet in 2024
01/11/24 Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders are private equity firms with 48% ownership, institutions own 24%
01/08/24 Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference
12/26/23 3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street
12/21/23 Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference
12/13/23 MSCLF: AAK1 Disclosed as Drug Target for DMD Program…
11/30/23 Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
LXRX Chatroom

User Image Diefreeandsell Posted - 9 minutes ago

$LXRX Sure looks like it's bottomed, would be nice for it to close above 200dma. So close...

User Image GA09 Posted - 1 hour ago

$LXRX Me thinks LXRX has put in a bottom. This one goes higher starting from Monday (Investors Day) and takes out the old time high. Good place to load up.

User Image Altgeld_ATW Posted - 4 hours ago

$LXRX Why aren't options available beyond Oct 2024? I recently invested in $VNDA that was in a similar situation.

User Image GA09 Posted - 4 hours ago

$LXRX Waiting to hear them on April 22nd. This time they have at least 4 hours to talk about INPEFA, what sales looks like, strategic plans, partnership discussions, etc. We may have seen the bottom in LXRX.

User Image MYFLAUT Posted - 6 hours ago

$LXRX LAST CHANCE !

User Image BullRun4 Posted - 15 hours ago

$LXRX Inepfa the new SOC for all heart failure patients. INPEFA superior efficacy vs. Farxiga and Jardiance.

User Image Themarketdon Posted - 16 hours ago

$LXRX Possible short squeeze tomorrow, the shorts not in the know Debanne’s crew will be nervous on what’s going to be said Monday

User Image macrossluvsrobotech Posted - 18 hours ago

$LXRX https://www.nbcnews.com/health/health-news/zepbound-shortage-eli-lilly-weight-loss-drug-rcna148232

User Image cobragene Posted - 21 hours ago

$LXRX Lets see if they pull the same crap (last second selloff) low life shorts

User Image Ihuarraqax Posted - 21 hours ago

$LXRX looks like we close near 1.6

User Image Diefreeandsell Posted - 22 hours ago

@BigT83 Some that have already been approved recently. $TGTX $CRSP $MDGL $IOVA $LXRX all down from highs so time entry right but keep in mind bios are once again out of favor due to interest rate jitters again as fed may not be cutting rates anytime soon as was expected.

User Image Jethro18 Posted - 23 hours ago

$LXRX 200 day MA 2.72 but please realize these up days are like the journey to .96 where they hurt you more than help because RSI rises and makes oversold even lower. This slide has been so similar to first slide to low.

User Image M4macho Posted - 23 hours ago

$LXRX wake up

User Image Altgeld_ATW Posted - 23 hours ago

$LXRX Hopefully the news shared on investors day will cause the stock price to go higher. Otherwise why bother?

User Image cobragene Posted - 1 day ago

$LXRX Ozempic and Mounjaro both have some serious side effects and neither are approved by the FDA for weight loss. both cost around $1,000 per month and both literally can't keep up with demand. Since Inpefa has literally no side effects, cost 1/2 that and is currently not approved for weight loss (either), I wonder if some people can get a script for Inpefa and do their own "private" weight loss "trial" If in fact Inpefa does work for weight loss as have been shown in the trials, and we are pursuing that in new trials... Just thinking out loud but it would be worth $ Billions as a stand along script.

User Image Anon_ymous1 Posted - 1 day ago

$LXRX from my perspective, worst case scenario is it appearing to be a 5$ instead of double digits. Might be delusional but I continue to buy more

User Image Daywalker777 Posted - 1 day ago

$LXRX if we thought $2.17 was a good buy, surely $1.65 is a better buy? Fock it…bought some more! Couldn’t resist. My only regret is buying my last batch at $2.5, but bought most in the $1.30’s. All will be forgiven if Lexi shows us some love soon. Hopefully investors day is not a dud

User Image bolderdash Posted - 1 day ago

$LXRX Let's hope Craig has more "air" time on the Investor Day. Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer.

User Image Jethro18 Posted - 1 day ago

$LXRX I suppose Coats will now say on investor day that investors should not avoid us.

User Image jonini Posted - 1 day ago

$LXRX 너무 꼴아박아서 조금 올라가는건 기별도 안가겠네..

User Image GA09 Posted - 1 day ago

$LXRX Stock will rally into Investors Day and then (depending on what they say) the stock either rallies or consolidates at this level. They sounded extremely positive in their ER and recent conferences. Expecting a lot of positive developments from their side on Investors Day.

User Image lob11 Posted - 1 day ago

@GA09 @cobragene $LXRX I'm very interested in what they have to say, but I temper any immediate optimism on these "investor days". I'm quite long here, but not going to get my hopes up for one day.

User Image Iman133 Posted - 1 day ago

$LXRX https://www.globenewswire.com/news-release/2024/04/18/2865364/0/en/Lexicon-Pharmaceuticals-to-Host-2024-Investor-Day.html

User Image cobragene Posted - 1 day ago

$LXRX I can't wait until Monday, Hopefully Investor Day information will help rid us of these pesky Shorts.

User Image Stock_Titan Posted - 1 day ago

$LXRX Lexicon Pharmaceuticals to Host 2024 Investor Day https://www.stocktitan.net/news/LXRX/lexicon-pharmaceuticals-to-host-2024-investor-aov2cbjw59zo.html

User Image Themarketdon Posted - 1 day ago

$LXRX More evidence Debanne’s heroes are covering their shorts Lexicons borrowing status change this morning to “easy to borrow”

User Image vrstock23 Posted - 1 day ago

$LXRX Did anyone register for this? Cannot register on link anymore as last date for reg was 15th. I hope they put link on website, which they haven't yet.

User Image Berakhot Posted - 1 day ago

$LXRX

User Image Berakhot Posted - 1 day ago

$LXRX

User Image Berakhot Posted - 1 day ago

$LXRX

Analyst Ratings
Needham Hold Apr 11, 24
Citigroup Buy May 31, 23
Needham Hold May 30, 23
Jefferies Hold Mar 7, 23
Citigroup Buy Nov 22, 22
Piper Sandler Overweight Aug 12, 22
Citigroup Buy Jul 1, 22
Wedbush Neutral Jan 29, 21
JP Morgan Neutral Jan 29, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
COATS LONNEL Chief Executive Offi.. Chief Executive Officer Nov 10 Buy 1.01 10,000 10,100 824,359 11/13/23
WADE JEFFREY L President and CFO President and CFO Sep 14 Buy 1.38 10,000 13,800 264,341 09/14/23
Invus US Partners LLC Director Director Aug 05 Buy 2.50 147,390 368,475 5,451,204 08/09/22
Artal International S.C.A. Director Director Aug 05 Buy 2.50 2,426,070 6,065,175 50,859,331 08/09/22